Virtusa releases cognitive adverse event case processing

Virtusa Corporation (NASDAQ GS: VRTU), a global business consulting and IT outsourcing company, has launched its latest pharmacovigilance (PV) solution for Adverse Event (AE) Intake and Cognitive Adverse Event Case Processing (AECP), the company said.

Built on pharmacovigilance and case management technology from Pegasystems, the solution enables life sciences companies to increase productivity while ensuring compliance, lowering costs, and enhancing patient safety.

Leveraging deep industry knowledge, extensive experience with life sciences companies, and strong expertise in Pega® Platform, the underlying Pega technology that powers Pega® Pharmacovigilance and case management, Virtusa expects the AECP solution to increase productivity and lower costs of overall PV operations by 50-80 percent.

Virtusa enables pharmaceutical companies and medical device manufacturers to streamline PV intake and AE case processing to address product, region, or regulatory requirements.

Virtusa is a global provider of information technology (IT) consulting and outsourcing services that accelerate business outcomes for Global 2000 companies and leading software vendors in banking and financial services, insurance, healthcare, telecommunications, technology, and media & entertainment.